The EC approved upadacitinib for active polyarticular JIA in children 2 years and older, based on phase 1 SELECT-YOUTH efficacy and safety data.
|Articles|October 4, 2021
Rheumatoid Arthritis Quiz: Rheumatoid Arthritis and Depression
Author(s)Ingrid Torjesen
Patients with rheumatoid arthritis have a higher risk of depression, but how much greater? Take this quiz to test your knowledge of the prevalence of depression.
Advertisement
How much more prevalent is depression in patients with rheumatoid arthritis compared with the general population?
Advertisement
Related to this article
August 2026 rheumatology highlights include FDA approval of brepocitinib for dermatomyositis and garetosmab-grts for FOP, and new trial data.
In RA-BRIDGE and RA-BRANCH, baricitinib failed to demonstrate VTE noninferiority in patients with RA enriched for thromboembolic risk factors.
A Phase 2a basket trial produced ACR50 responses in 71% of refractory RA patients at 6 months.
Advertisement
Advertisement